ZBH — Zimmer Biomet Holdings, Inc.

Summary of Zimmer Biomet (ZBH) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Sales Growth: Q3 2025 sales grew 5% on an organic constant currency basis, with total net sales reaching $2 billion, a 9.7% increase on a reported basis.
• U.S. Performance: U.S. business grew 5.6%, the best performance since mid-2023, driven by strong adoption of new products.
• Adjusted EPS: Adjusted earnings per share was $1.90, up 9.2% year-over-year, despite dilution from the Paragon 28 acquisition and increased interest expenses.
• Gross Margin: Adjusted gross margin improved to 72.6%, attributed to lower manufacturing costs and favorable product mix.
• Free Cash Flow: Generated $278 million in free cash flow for the quarter, with year-to-date free cash flow at approximately $800 million.

2. Strategic Updates and Business Highlights

• Product Innovation: Continued momentum from new product launches, including Persona OsseoTi and Oxford knees, with significant market adoption. Robotics and navigation sales increased 20.3%.
• Acquisitions: Closed the acquisition of Monogram Technologies, enhancing the robotics portfolio. Integration of Paragon 28 is progressing well, with organic growth in the upper single digits.
• Market Dynamics: Positive trends in demographics and surgical environments, particularly in the U.S. Ambulatory Surgical Centers (ASCs), are expected to drive future growth.

3. Forward Guidance and Outlook

• Revenue Guidance: Updated full-year organic constant currency revenue growth expectations to 3.5% to 4%, down from 3.5% to 4.5%. Maintained adjusted EPS guidance of $8.10 to $8.30.
• Market Considerations: Guidance reflects anticipated continued weakness in restorative therapies, challenges in certain international markets, and a slowdown in the U.S. revision market for hips and knees.

4. Bad News, Challenges, or Points of Concern

• Emerging Market Weakness: Late-quarter cancellations in Eastern Europe and Latin America negatively impacted growth by approximately 120 basis points.
• Restorative Therapies Decline: The restorative therapies segment faced challenges, with a significant decline attributed to commercial execution issues and reimbursement changes.
• Market Share Concerns: Although U.S. growth improved, there are ongoing concerns about market share losses, particularly in the knee segment, which may require further innovation and execution improvements to address.

5. Notable Q&A Insights

• Guidance Philosophy: CEO Ivan Tornos acknowledged the need for a more measured approach to guidance after unexpected late-quarter challenges. He emphasized that future guidance will exclude non-core areas to avoid overpromising.
• Capital Allocation Strategy: CFO Suky Upadhyay highlighted a disciplined approach to capital allocation, focusing on high-growth acquisitions while maintaining flexibility for share buybacks.
• Innovation Pipeline: Tornos discussed the three waves of innovation, indicating that the first wave (catching up) is progressing well, while the second wave (customer-centric innovation) is underway, with promising products like iodine-coated implants expected to drive future growth.
• Commercial Execution: Changes in leadership and incentives are being implemented to enhance commercial execution, with accountability measures now in place across various levels of the organization.

Overall, Zimmer Biomet demonstrated solid financial performance in Q3 2025, driven by innovation and strategic acquisitions, but faced challenges in emerging markets and specific product segments that may impact future growth. The company remains optimistic about its long-term trajectory while addressing current headwinds.